1937 related articles for article (PubMed ID: 20485259)
21. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
Mahadevan U; Cucchiara S; Hyams JS; Steinwurz F; Nuti F; Travis SP; Sandborn WJ; Colombel JF
Am J Gastroenterol; 2011 Feb; 106(2):214-23; quiz 224. PubMed ID: 21157441
[TBL] [Abstract][Full Text] [Related]
22. Review article: Infliximab therapy for inflammatory bowel disease--seven years on.
Rutgeerts P; Van Assche G; Vermeire S
Aliment Pharmacol Ther; 2006 Feb; 23(4):451-63. PubMed ID: 16441465
[TBL] [Abstract][Full Text] [Related]
23. [TNF-alpha blocking therapy in chronic inflammatory bowel disease].
Molnár T
Orv Hetil; 2009 Sep; 150(38):1773-9. PubMed ID: 19740722
[TBL] [Abstract][Full Text] [Related]
24. Adalimumab in ulcerative colitis: hypes and hopes.
Fiorino G; Peyrin-Biroulet L; Repici A; Malesci A; Danese S
Expert Opin Biol Ther; 2011 Jan; 11(1):109-16. PubMed ID: 21133817
[TBL] [Abstract][Full Text] [Related]
25. Maintenance therapy with certolizumab pegol for Crohn's disease.
Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
[TBL] [Abstract][Full Text] [Related]
26. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
Gisbert JP; Marín AC; McNicholl AG; Chaparro M
Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
[TBL] [Abstract][Full Text] [Related]
27. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
28. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
29. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
Verma HD; Scherl EJ; Jacob VE; Bosworth BP
J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
[TBL] [Abstract][Full Text] [Related]
30. Mucosal healing and anti TNFs in IBD.
van Assche G; Vermeire S; Rutgeerts P
Curr Drug Targets; 2010 Feb; 11(2):227-33. PubMed ID: 20210770
[TBL] [Abstract][Full Text] [Related]
31. Crohn's disease in patients who fail infliximab therapy: what does the future hold?
Abreu MT
Rev Gastroenterol Disord; 2007; 7 Suppl 1():S20-6. PubMed ID: 17392630
[TBL] [Abstract][Full Text] [Related]
32. Mucosal healing with anti-TNF antibodies.
Chevaux JB; Vavricka SR; Rogler G; Lakatos PL; Schoepfer A; Peyrin-Biroulet L
Digestion; 2012; 86 Suppl 1():16-22. PubMed ID: 23051722
[TBL] [Abstract][Full Text] [Related]
33. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
Feagan BG; Sandborn WJ; Wolf DC; Coteur G; Purcaru O; Brabant Y; Rutgeerts PJ
Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
[TBL] [Abstract][Full Text] [Related]
35. The safety of biologic agents in the treatment of inflammatory bowel disease.
Shepela C
Minn Med; 2008 Jun; 91(6):42-5. PubMed ID: 18616021
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumour necrosis factor treatment of inflammatory bowel disease in liver transplant recipients.
Mohabbat AB; Sandborn WJ; Loftus EV; Wiesner RH; Bruining DH
Aliment Pharmacol Ther; 2012 Sep; 36(6):569-74. PubMed ID: 22779779
[TBL] [Abstract][Full Text] [Related]
37. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.
Ng SC; Plamondon S; Gupta A; Burling D; Kamm MA
Aliment Pharmacol Ther; 2009 Oct; 30(7):757-66. PubMed ID: 19575762
[TBL] [Abstract][Full Text] [Related]
38. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
Oussalah A; Roblin X; Laharie D; Filippi J; Flamant M; Faure P; Phelip JM; Bigard MA; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(8):854-63. PubMed ID: 19764940
[TBL] [Abstract][Full Text] [Related]
39. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease.
Williams CJ; Peyrin-Biroulet L; Ford AC
Aliment Pharmacol Ther; 2014 Mar; 39(5):447-58. PubMed ID: 24444171
[TBL] [Abstract][Full Text] [Related]
40. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]